Apellis Pharmaceuticals (FRA:1JK) EPS (Basic) : €-3.20 (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Apellis Pharmaceuticals EPS (Basic)?

Apellis Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Mar. 2024 was €-0.50. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2024 was €-3.20.

Apellis Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2024 was €-0.50. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-3.20.

Apellis Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2024 was €-0.50. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was -3.20.

During the past 3 years, the average EPS without NRI Growth Rate was -7.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was -14.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was -33.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 11 years, Apellis Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 0.80% per year. The lowest was -89.90% per year. And the median was -36.60% per year.

Apellis Pharmaceuticals EPS (Basic) Historical Data

The historical data trend for Apellis Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apellis Pharmaceuticals EPS (Basic) Chart

Apellis Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-4.41

-3.77

-7.82

-5.81

-4.08

Apellis Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EPS (Basic)	Get a 7-Day Free Trial															-1.46	-0.94	-1.10	-0.67	-0.50

Apellis Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Apellis Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-484.752	-	0)	/	118.678
	=	-4.08

Apellis Pharmaceuticals's Basic EPS for the quarter that ended in Mar. 2024 is calculated as

Basic EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-61.109	-	0)	/	122.957
	=	-0.50

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.20

Apellis Pharmaceuticals (FRA:1JK) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Apellis Pharmaceuticals EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Apellis Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Apellis Pharmaceuticals (FRA:1JK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apellis Pharmaceuticals Inc (FRA:1JK) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

APLS:USA

Address

100 Fifth Avenue, Waltham, MA, USA, 02451

Website

https://www.apellis.com

Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade.

Apellis Pharmaceuticals (FRA:1JK) Headlines

No Headlines